Because the pending merger fundamentally changes the company's share structure, the existing analyst data is treated as context rather than a current consensus. Two dated targets remain on record: TD Cowen's Kyle Boucher set a $1.35 target with a Hold rating in November 2025, and Jefferies carried a $1.75 target with a Buy rating from the same period; KeyBanc's Paul Knight had moved to a Sector Weight (no target) in February 2025. That implies a mean near $1.55. However, these figures were issued before the Treeline deal was announced and do not account for the planned share issuance or reverse split, so they are not used as the central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $1.15 objective instead comes from identifiable public discussion: it is the level at which LAB shares traded before the reverse-merger announcement, and financial commentary has repeatedly cited it as the benchmark from which the stock has fallen. It is a recovery reference point tied to the value-creation debate around the deal, not an official analyst consensus.
LAB recently closed near $0.54, after slipping from roughly $0.71 earlier in mid-November 2026 as investors weighed the upcoming vote. Reaching $1.15 would require an advance of about 113%, a very large move for any equity and one that would still leave the shares inside their prior 52-week range of roughly $0.62 to $1.72.
The theoretical path runs through merger completion: approval would see Treeline holders take about 84% of the combined company while existing LAB holders retain roughly 16%, with a reverse split of between 1-for-20 and 1-for-40 intended to reset the share price. Because of that split, any recovery toward $1.15 on a pre-split basis is a different proposition from the post-split quote investors would actually see, making direct price comparisons unusually difficult.
Standard BioTools has been shrinking toward profitability. After selling its SomaLogic proteomics assets to ILMN (Illumina) for substantial upfront cash, the company reported roughly $84.6 million in continuing revenue for 2025 and guided to $80 million to $85 million for 2026. Cost reductions have improved adjusted EBITDA, with management targeting positive adjusted EBITDA exiting 2026. The balance sheet also holds meaningful cash, and shareholders would receive contingent value rights (CVRs) tied to proceeds from planned divestitures, which some argue offsets part of the merger's dilution.
The transaction's own mechanics are the principal obstacle. Pro forma net tangible book value per share drops from roughly $1.38 to about $0.43 for existing holders, and up to about two billion new shares would be issued. If the vote fails, the company could face a termination fee, and a reverse split alone does not create value. The business also remains unprofitable, faces limited growth in its continuing operations, and has drawn shareholder demand letters alleging inadequate proxy disclosure — a litigation overhang ahead of the decision.
The shares have been trading near the bottom of a 52-week range of about $0.62 to $1.72, and a recent intraday probe below $0.40 pushed them to new lows. The $1.00 level is significant as both a psychological round number and NASDAQ's minimum bid-price threshold — one reason the reverse split is on the ballot. The $1.15 target sits within the former trading range, but the stock would first need to reclaim and hold above roughly $0.60, an area that has recently acted as resistance on the way down.
Analyst targets generally reflect a roughly 12-month horizon, but the dated LAB targets predate the merger and carry little forward-looking weight. The immediate catalyst is the November 19, 2026 shareholder vote on the share issuance and reverse split, with a targeted closing in the fourth quarter. Investors should monitor whether the deal is approved, the final reverse-split ratio, the treatment and value of the CVRs, the company's next quarterly results and adjusted EBITDA progress, and any fresh analyst commentary once the combined entity's structure is settled.
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals have become a practical part of staying on top of names like this one. They apply artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals that factor in technical behavior and shifting market conditions. For an event-driven situation where headlines around the merger are driving price action, these signals can help surface opportunities and track changes without replacing your own due diligence. I find them useful for layering additional context onto the fundamental picture.
The $1.15 figure is a recovery benchmark drawn from public discussion, not a current analyst consensus, and it sits far above the latest price near $0.54 — a very large required move of about 113%. Support could come from the Treeline combination, a cash-heavy balance sheet, cost discipline, and the contingent value rights attached to asset sales. Against that stand the structural realities of the deal: roughly 84% dilution to new holders, a potential reverse split, continued losses, and litigation risk. The two dated analyst targets ($1.35 and $1.75) show genuine disagreement even before accounting for the merger, underscoring how much rests on the vote and its execution rather than on ordinary operating performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for LAB moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In 45 of the 49 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LAB as a result. In 84 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for LAB turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 47 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
LAB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for LAB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Following a +10.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 202 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (4.142). P/E Ratio (2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of integrated fluidic circuit systems
Industry MedicalNursingServices